Incidence of soft tissue injury and neuropathy after embolo/sclerotherapy for congenital vascular malformation  by Lee, Kyung-Bok et al.
Incidence of soft tissue injury and neuropathy
after embolo/sclerotherapy for congenital vascular
malformation
Kyung-Bok Lee, MD,a Dong-Ik Kim, MD,a Se-Keon Oh, MD,a Young-Soo Do, MD,b Keon-Ha Kim, MD,b
and Young-Wook Kim, MD,a Seoul, South Korea
Purpose: Embolo/sclerotherapy is an important treatment modality for vascular malformations, but the rates and results
of the complications associated with embolo/sclerotherapy are not well known. We report the incidence and outcome of
soft tissue injury and neuropathy after performing embolo/sclerotherapy for congenital vascular malformations (CVMs)
classified according to the Hamburg classification.
Methods: Among 1823 patients with CVM, 573 were treated with embolo/sclerotherapy. We retrospectively reviewed 68
patients (31 males, 37 females; mean age, 20.0 years) with soft tissue injury and 49 patients (16 males, 33 females; mean
age, 21.2 years) with neuropathy. The indications for embolo/sclerotherapy for CVM were that the CVMs affected the
quality of life, such as a symptomatic or trauma-prone lesion or a lesion that was impairing the function of a limb, and
the lesions that were located near a life-threatening vital area, including the airway. As embolo/sclerotherapy agents,
absolute or 80% ethanol, N-butyl cyanoacrylate (NBCA), and various types of coils or contour particles were used in
various combinations, either at the same time or in phases, depending on the location, severity, and extent of the CVM.
Results: The incidence of soft tissue injury was 29.4% (42 of 143) for the arteriovenous shunting type and 8% (22 of 273)
for the venous type. No soft tissue injuries occurred in the patients with arterial and lymphatic malformations. Of the 68
patients with soft tissue injury, 40 lesions healed with conservative management, and 28 lesions needed surgery, including
escharectomy, skin graft, or amputation. The incidence of neuropathy was 10.9% (30 of 273) for the venous CVM. No
neuropathy occurred in the patients with arterial malformations. Of the 49 patients with neuropathy, 42 recovered at a
mean period of 5.3 months, but seven did not.
Conclusion: Soft tissue injuries occurred in 11.9% of patients (68 of 573) and neuropathies occurred in 8.6% (49 of 573)
after undergoing embolo/sclerotherapy. Most of these complications recovered by themselves (58.9% from soft tissue
injury and 85.1% from neuropathy). Our results suggest that embolo/sclerotherapy has an acceptable incidence of soft
tissue injury and neuropathy, when considering the effect that the CVM had on the quality of life before treatment, so
embolo/sclerotherapy is recommended as a treatment modality for CVM. (J Vasc Surg 2008;48:1286-91.)Despite the advances in vascular medicine, congenital
vascular malformations (CVMs) are still a challenge among
the many vascular diseases. Vascular malformations can
present with a variety of symptoms and an unpredictable
course.1,2
Complete eradication of the nidus of a CVM has been
known to be the therapeutic option for achieving a poten-
tial cure. Yet, complete surgical eradication of the nidus of
a CVM is rarely possible for most of the infiltrating type of
CVMs, except for small, localized, and surgically accessible
lesions.3,4 Blocking the route for embolo/sclerotherapy by
ligation of the feeding arteries and partial excision of the
nidus might interfere with embolo/sclerotherapy, and
the outcome is then worsened.5,6
Once the accurate diagnosis of the CVM is established
in our hospital, further decisions are referred to the multi-
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1286disciplinary team of the CVM clinic, and this meeting of the
team is held semimonthly. The multidisciplinary team is
made up of special departments related to the management
of CVM, including vascular surgery, plastic and reconstruc-
tive surgery, orthopedic surgery, interventional and diag-
nostic radiology, physical medicine, and rehabilitation. The
crucial decision for whether a lesion is indicated for treat-
ment is made after a consensus among the multidisciplinary
team members. Our vascular center previously reported
that the diagnosis and management of CVMs by a multi-
disciplinary approach that integrates surgical therapy with
embolism and sclerotherapy appears to improve the results
and management with limited morbidity.7-9
Embolo/sclerotherapy may be an effective treatment
method because no recurrence has been observed during
the relative long-term observation period and the morbid-
ity has been acceptable.7,10 Yet, it is not well known what
type of vascular malformation is more susceptible to com-
plications such as soft tissue injury or neuropathy after
embolo/sclerotherapy has been performed. We report the
incidence of soft tissue injury and neuropathy complica-
tions and the outcome (treatment methods, duration, and
the result) of the complications after embolo/sclerotherapy
according to CVM type according to the Hamburg classi-
fication.
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 5 Lee et al 1287METHODS
We treated 573 patients among the 1823 patients with
CVMs who were investigated from January 1995 to De-
cember 2006. The indications for sclerotherapy were:
1. lesions with symptoms and signs such as pain, discom-
fort, a heavy sensation, difficult mobility and difficult
joint motion, swelling, a limited range of motion, ulcer,
hemorrhage or stasis dermatitis, or a combination;
2. lesions that caused significant functional impairment or
a severe cosmetic deformity;
3. lesions located at a trauma-prone region, such as the
knee, ankle, foot, elbow, wrist, and hand, with an in-
creased risk of complications such as hemarthrosis;
4. lesions located at a potentially life-threatening vital area
that compromised seeing, hearing, eating, or breathing;
for example, a lesion near the airway or an eyelid lesion
that blocked sight, and especially in infants; or
5. lesions combined with abnormal long-bone growth
with a limb length discrepancy that was due to vascular
bone syndrome.7,11,12
The 573 patients were managed by a multidisci-
plinary approach with full integration of embolo/sclerother-
apy and surgical intervention. As embolo/sclerotherapy
agents, absolute or 80% ethanol, N-butyl cyanoacrylate
(NBCA), and various types of coils or contour particles
made from polyvinyl alcohol foam, or both, were used in
various combinations, either simultaneously or in stages,
depending on the location, severity, and extent of the
CVM.
Absolute or 80% ethanol was used as the main agent for
treating the surgically inaccessible lesions13 and was admin-
istered by transarterial, transvenous, or direct puncture
injection. The route depended on the anatomic or hemo-
dynamic status of the CVM. Direct puncture injection was
done in all of the venous and lymphatic type CVMs. For the
arterial and arteriovenous (AV) shunting-type CVMs, a
combined approach was done, such as the intra-arterial and
direct puncture technique for embolo/sclerotherapy. The
NBCA glue was mainly used for treating the surgically
excisable lesions as the preoperative embolo/sclerotherapy
to facilitate its surgical removal and reduce morbidity dur-
ing the subsequent surgical therapy.
The treatment strategy for soft tissue injury was deter-
mined by the severity of the injury. Simple wound dressing
was done first. Lesions that became infected required anti-
biotics and débridement, or drainage, or both. Wounds
that were not healed by dressing and that involved deeper
tissue injury, such as muscle or tendon injury, necessitated
subsequent plastic reconstructive work (eg, split-thickness
skin graft). If eschar was formed as a consequence of soft
tissue injury and the skin became contracted, then eschar-
ectomy was done. All of the patients who needed amputa-
tions had the AV-shunting extratruncular (ET)-infiltrating
type of CVM.
Nerve injury was identified by measuring the nerve
conduction velocity and performing electromyography forthe patients who complained of motor or sensory impair-
ment after embolo/sclerotheapy. Nerve injury was man-
aged by arranging for splinting or physical therapy, or both,
and pain management was done during the healing phase.
We used various noninvasive and invasive tests for the
diagnosis of CVM. Noninvasive tests such as duplex ultra-
sound imaging, computed tomography, magnetic reso-
nance imaging with gadolinium contrast,14 transarterial
lung perfusion scan, and whole body blood pool scan were
first used for the diagnosis, and then selective catheter
contrast angiography was done to establish a more precise
diagnosis and create a therapeutic plan. When the CVM
was diagnosed, then further review was done and the
treatment plan was made by the multidisciplinary team.
Approval from the Institutional Review Board at our
hospital was obtained for conducting a retrospective review
of the patients’ medical records. Written consent for the
procedure was obtained from all the patients.
RESULTS
Among the 573 patients treated with embolo/sclero-
therapy, 68 patients (31 males and 37 females; mean age,
20.0 years) with soft tissue injury and 49 patients (16 males
and 33 females; mean age, 21.2 years) with neuropathy
were included. The embolo/sclerotherapy agents we used
were ethanol in 410, ethanolamine oleate in 32, andNBCA
glue in 24. Soft tissue injury occurred in 64 of the 410
patients for whom ethanol was used, in two of the 32
patients for whom ethanolamine oleate was used, and in
two of the 24 patients for whom glue was. Neuropathy
occurred in 48 patients of the 393 patients in whom etha-
nol was used and in 1 of the 32 patients in whom ethanol-
amine oleate was used.
Soft tissue injury (Fig) occurred in 68 of the 573
patients treated with embolo/sclerotherapy. The incidence
of soft tissue injury according to theHamburg classification
is described in Table I. There were no soft tissue injuries in
the patients with arterial and lymphatic malformations. Soft
tissue injuries did occur 42 of 142 patients (29.4%) with the
AV shunting type, which was the largest proportion, in 22
of 272 the patients with the ET type, and in four of 53
patients with the combined type of CVM. No soft tissue
injury occurred in the patients with the ET type after
embolo/sclerotheapy. The rates of soft tissue injury were
more common for the infiltrating type than for the limited
type of the ET form of CVM (13.2% vs 9.7%, respectively).
Table II presents the methods of treatment for soft
tissue injury according to the types of CVM. Conservative
treatment, such as applying a simple dressing, resulted in
healing in 40 patients with soft tissue injury in an average of
2.7 months (range, 1-6 months). The healing time for the
40 patients differed according to the depth of the lesions.
Healing took 2.6 months if lesions involved the skin, but
took 3.3 months if they involved the subcutaneous tissue.
Lesions that involved muscle did not heal with conservative
management (Table II).
The incidence of soft tissue injury according to the loca-
tion of the CVM lesion was 20.4% for lesions in the upper
wer e
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extremities (22 of 154) and perineum/genitalia (2 of 14),
9.1% for lesions in the pelvis (3 of 33), 7.5% for lesions in
the head and neck (16 of 213), and 6.4% for lesions in the
thorax (3 of 47). Among 68 soft tissue injuries, one oc-
curred in a patient with venous malformation involving the
tongue and lip.
Neuropathy occurred in 49 patients of the 573 patients
who were treated with embolo/sclerotherapy. The inci-
dence of neuropathy according to the Hamburg classifica-
tion is described in Table I. The rates of neuropathy were
10.9% (30 of 273) for the venous type, 9% (13 of 143)
for the AV-shunting type, 7% (4 of 54) for the combined
type, and 2% (2 of 102) for the lymphatic type. No
neuropathy occurred with the arterial type. All of the
neuropathies occurred in the ET form (49 of 567). The
rates of neuropathy were 7.5% (28 of 371) for the infil-
trating form and 10.7% (21 of 196) for the limited form. Of
Fig. Soft tissue injuries after embolo/sclerotherapy. A,
the vulvar area. C, Arteriovenous malformation of the lo
Table I. Patients with soft tissue injury and neuropathy ac
on the Hamburg classification)
Types of CVM No. Form N
Arterial 1 ET
Limited
Venous 273 ET 27
Limited 5
Infiltrating 21
T
Lymphatic 102 ET 9
Limited 8
Infiltrating 1
T
AV shunting 143 ET 14
Limited 4
Infiltrating 9
T
Combined 54 ET 5
Limited 1
Infiltrating 4
Total 573 T
AV, Arteriovenous; ET, extratruncular form; T, truncular form.the 49 patients with neuropathy, 42 spontaneously recov-ered at an average of 5.3 months (range, 1-24months), but
seven did not.
Discomfort was minimal in 33 of the 49 neuropathy
patients so specific management was not needed. Four
patients with permanent motor nerve injury have received
an orthosis. Ankle-foot orthoses for three patients with
peroneal nerve injury and an orthotic insole for one patient
with tibial nerve injury were prescribed. Among the 42
patients who spontaneously recovered from neuropathy,
22 patients had sensory nerve injury, five had motor
nerve injury, and 15 had an injury of both nerves (Table
III). Of the remaining seven patients who did not re-
cover, one had sensory nerve injury, three patients had
motor nerve injury, and three had both motor and sensory
nerves injury.
The rates of neurovascular involvement were 4.7% (2 of
42) for the patients who recovered from neuropathy and
28.5% (2 of 7) for the patients who did not recover from
us malformation of the lip. B, Venous malformation of
xtremity.
ing to the type of congenital venous malformation (based
Soft tissue injury (n  68) Neuropathy (n  49)
0 0
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0 0
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1neuropathy. All of the involved nerves were in the extrem-
n, and
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tion of CVM was 16.7% (18 of 108) for the upper extrem-
ities, 8.9% (19 of 213) for the head and neck, 16.7% (18 of
108) for the upper extremities, 7.1% (11 of 154) for the
lower extremities, and 2.1% (1 of 47) for the thorax. No
neuropathies developed in the abdomen (n  4), pelvis
(n  33), or perineum and genitalia (n  14).
DISCUSSION
Although much effort is being made to improve the
clinical management of CVMs, they still present a major
challenge to physicians and even to the most experienced
clinicians.Most of the information on CVMs, including the
new concept of a multidisciplinary approach that is based
on the Hamburg classification, the modern methodologies
for clinical and laboratory study, and the indications for the
proper treatment and modality, together with the assess-
ment criteria of the treatment responses, has already been
explained in detail in previous publications.7,13,15
Soft tissue injuries occurred frequently in the case of a
CVM with skin or subcutaneous tissue involvement, and
these injuries can be easily predicted with using various
diagnostic modalities such as duplex ultrasound scanning
or magnetic resonance imaging. As a result, all of the
patients who needed amputation had the AV-shunting
ET-infiltrating type of CVM.
The possible mechanisms of neuropathy associated
Table II. Treatment methods for 68 patients with soft tis
venous malformation
Types of CVM
(n  68) No. (%)
Conservati
(n  40)
Venous ET 22 (32)
Limited 6 4
Skin 3 1
Subcutaneous tissue 1 1
Muscle 2 2
Infiltrating 16 9
Skin 14 9
Subcutaneous tissue 1 0
Muscle 1 0
AV shunting ET 42 (62)
Limited 12 10
Skin 12 10
Infiltrating 30 14
Skin 26 13
Subcutaneous tissue 2 1
Muscle 2 0
Combined 4 (6)
Limited 1 0
Skin 1 0
Infiltrating 3 3
Skin 2 2
Subcutaneous tissue 1 1
AV, Arteriovenous; CVM, congenital venous malformation; ET, extratrunc
aThe four amputations were performed in patients with extensive necrosis of
1 each above knee amputation, below knee amputation, forearm amputatiowith embolo/sclerotheapry were (1) extravasation and dif-fusion of ethanol around a nerve trunk, (2) obstruction of
the vasa nervorum, and (3) the severe swelling associated
with compartment syndrome and subsequent nerve injury.
After embolo/sclerotherapy is performed, the ethanol can
easily diffuse to the tissue adjacent to a venous malforma-
tion because the venous malformation has thinner vessel
walls.
There have been few reports about embolo/sclerother-
apy complicated by nerve injury. Liang et al16 reported
recurrent nerve injury that caused vocal cord paralysis after
embolization of a patent ductus arteriosus in three infants.
Quinn et al17 published a small series of patients who
underwent catheter-guided cisplatin chemotherapy for pel-
vic cancers and femoral and sciatic nerve lesions developed.
In another previous study, stent grafting to treat an abnor-
mal aortic aneurysm along with embolization of the iliac
arteries was complicated by lower extremity weakness and
fecal incontinence in one patient.18 John et al19 reported a
patient with sciatic neuropathy after endovascular treat-
ment of a limb vascular malformation.
In conclusion, further study will be needed to analysis
the risk factors and to investigate the long-term results for
the complications of soft tissue injury and neuropathy that
occur in patients who undergo embolo/sclerotherapy for a
CVM.
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